

Ketchum Steven B  
Form 4  
February 01, 2019

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Ketchum Steven B

2. Issuer Name and Ticker or Trading Symbol  
AMARIN CORP PLC\UK [AMRN]

5. Relationship of Reporting Person(s) to Issuer  
(Check all applicable)

(Last) (First) (Middle)  
C/O AMARIN PHARMA,  
INC., 1430 ROUTE 206  
(Street)

3. Date of Earliest Transaction  
(Month/Day/Year)  
01/31/2019

\_\_\_\_ Director \_\_\_\_\_ 10% Owner  
 Officer (give title below) \_\_\_\_\_ Other (specify below)  
Chief Scientific Officer

BEDMINSTER, NJ 07921  
(City) (State) (Zip)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(D)	Price
Ordinary Shares <sup>(1)</sup> <sub>(2)</sub>	01/31/2019		M		2,604	A	\$ 1.4
					343,901	D	<sup>(3)</sup>
Ordinary Shares <sup>(1)</sup> <sub>(2)</sub>	01/31/2019		M		4,167	A	\$ 2.5
					348,068	D	<sup>(3)</sup>
Ordinary Shares <sup>(1)</sup> <sub>(2)</sub>	01/31/2019		M		2,770	A	\$ 2.95
					350,838	D	<sup>(3)</sup>
Ordinary Shares <sup>(1)</sup> <sub>(2)</sub>	01/31/2019		S		9,541	D	\$ 17.4903
					341,297	D	<sup>(3)</sup>

Edgar Filing: Ketchum Steven B - Form 4

<u>(2)</u>					<u>(4)</u>		
Ordinary Shares <u>(1)</u> <u>(2)</u>	01/31/2019	M	26,666 <u>(5)</u>	A	<u>(6)</u>	367,963	D <u>(3)</u>
Ordinary Shares <u>(1)</u> <u>(2)</u>	01/31/2019	M	29,000 <u>(7)</u>	A	<u>(6)</u>	396,963	D <u>(3)</u>
Ordinary Shares <u>(1)</u> <u>(2)</u>	01/31/2019	M	26,000 <u>(8)</u>	A	<u>(6)</u>	422,963	D <u>(3)</u>
Ordinary Shares <u>(1)</u> <u>(2)</u>	01/31/2019	F <sup>(9)</sup>	40,482	D	\$ 16.94	382,481	D <u>(3)</u>
Ordinary Shares <u>(1)</u> <u>(2)</u>	02/01/2019	S	27,989	D	\$ <u>(10)</u> 17.0602	354,492	D <u>(3)</u>

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Security (Instr. 3 and 4)	Amount or Number of Shares	
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	\$ 1.4	01/31/2019		M		<u>(11)</u>	01/31/2026	Ordinary Shares <u>(2)</u>	2,604
Stock Option (Right to Buy)	\$ 2.5	01/31/2019		M		<u>(12)</u>	07/06/2025	Ordinary Shares <u>(2)</u>	4,167
Stock Option (Right to Buy)	\$ 2.95	01/31/2019		M		<u>(13)</u>	01/31/2027	Ordinary Shares <u>(2)</u>	2,770

Buy)

Restricted Stock Units <sup>(14)</sup>	\$ 0	01/31/2019	M	26,666	<u>(5)</u>	<u>(6)</u>	Ordinary Shares <sup>(2)</sup>	26,666
Restricted Stock Units <sup>(14)</sup>	\$ 0	01/31/2019	M	29,000	<u>(7)</u>	<u>(6)</u>	Ordinary Shares <sup>(2)</sup>	29,000
Restricted Stock Units <sup>(14)</sup>	\$ 0	01/31/2019	M	26,000	<u>(8)</u>	<u>(6)</u>	Ordinary Shares <sup>(2)</sup>	26,000
Restricted Stock Units <sup>(14)</sup>	\$ 0	02/01/2019	A	38,200	<u>(15)</u>	<u>(6)</u>	Ordinary Shares <sup>(2)</sup>	38,200
Stock Option (Right to Buy)	\$ 16.88	02/01/2019	A	53,500	<u>(16)</u>	02/01/2029	Ordinary Shares <sup>(2)</sup>	53,500

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Ketchum Steven B C/O AMARIN PHARMA, INC. 1430 ROUTE 206 BEDMINSTER, NJ 07921			Chief Scientific Officer	

## Signatures

/s/ Joseph Kennedy, by power of attorney  
02/01/2019

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Multiple reportable transactions are reported in the Form 4 including grants of options, grants of restricted stock units, exercise of previously granted options, vesting of previously granted restricted stock units and sale of certain shares. The market sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
- (2) The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- (3) Please see the section titled "Remarks" below for additional information.
- (4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$17.09 to \$17.90, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- (5)

## Edgar Filing: Ketchum Steven B - Form 4

On February 1, 2016, the Reporting Person was granted 80,000 Restricted Stock Units ("RSUs") under the Amarin Corporation plc 2011 Stock Incentive Plan (the "Plan"). These RSUs vest in three equal installments on each of January 31, 2017, January 31, 2018 and January 31, 2019. The third and final vesting event occurred on January 31, 2019.

- (6) Not applicable.
- (7) On February 1, 2017, the Reporting Person was granted 87,000 RSUs under the Plan. These RSUs vest in three equal installments on each of January 31, 2018, January 31, 2019 and January 31, 2020. The second vesting event occurred on January 31, 2019.
- (8) On February 1, 2018, the Reporting Person was granted 78,000 RSUs under the Plan. These RSUs vest in three equal installments on each of January 31, 2019, January 31, 2020 and January 31, 2021. The first vesting event occurred on January 31, 2019.
- (9) Represents withholding by the Issuer of shares in respect of tax liability incident to the vesting of a security issued in accordance with Rule 16b-3, and not a market sale of securities.
- (10) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$16.81 to \$17.62, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- (11) On February 1, 2016, the Reporting Person was granted an option to purchase 125,000 Ordinary Shares under the Plan. The shares subject to this option shall vest and become exercisable in 48 equal monthly installments on the last day of each month that began on February 29, 2016.
- (12) On July 6, 2015, the Reporting Person was granted an option to purchase 200,000 Ordinary Shares under the Plan. The shares subject to this option shall vest and become exercisable in 48 equal monthly installments on the last day of each month that began on July 31, 2015.
- (13) On February 1, 2017, the Reporting Person was granted an option to purchase 133,000 Ordinary Shares under the Plan. The shares subject to this option shall vest and become exercisable in 48 equal monthly installments on the last day of each month that began on February 28, 2017.
- (14) Each RSU represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion.
- (15) On February 1, 2019, the Reporting Person was granted 38,200 RSUs under the Plan. These RSUs vest in three equal installments on each of January 31, 2020, January 31, 2021 and January 31, 2022.
- (16) On February 1, 2019, the Reporting Person was granted an option to purchase 53,500 Ordinary Shares under the Plan. The shares subject to this option shall vest and become exercisable in 16 equal quarterly installments starting on May 15, 2019.

### Remarks:

In the case of a Change of Control (as defined in the Plan), the grants described in this Form 4 vest in full. As of the date of this filing, the Reporting Person is not a party to any such Change of Control.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.